SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, Eli Lilly, and Innovent Biologics
* H tr p da, trng da I TNG S DNG: Ngi trng thnh mun tng cng sc khe cho da
Each spray delivers 166mcg, providing a consistent and easy-to-manage dosing approach
It creates false confidence in an incorrect dose
Innovations in epigenetics and pharmacology, such as the development of drugs like Apabetalone and TOTUM-63, offer promising adjuncts to lifestyle interventions by targeting the underlying biological mechanisms to prevent the onset of type 2 diabetes and its complications